Trial Profile
Post-marketing Surveillance of Long-term Administration of Inovelon Tablets in Patients With Lennox-Gastaut Syndrome
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 23 Feb 2023
Price :
$35
*
At a glance
- Drugs Rufinamide (Primary)
- Indications Lennox-Gastaut syndrome
- Focus Adverse reactions; Therapeutic Use
- Sponsors Eisai Co Ltd
- 30 Nov 2022 Status changed from recruiting to completed.
- 01 Nov 2022 Planned End Date changed from 30 Nov 2022 to 15 Nov 2022.
- 01 Nov 2022 Planned primary completion date changed from 30 Nov 2022 to 15 Nov 2022.